Laurus Labs completes US FDA inspection at Unit 2, Visakhapatnam
Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010), a leading research and development driven pharmaceutical company has completed the US Food and Drug Administration (USFDA) inspection of its Unit - 2 (FDF&API integrated facility), located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh, with two observations which are procedural in nature.
This is a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from 04 November, 2019 - 08 November, 2019.